Format

Send to

Choose Destination
Sci Transl Med. 2015 Mar 25;7(280):280ps7. doi: 10.1126/scitranslmed.aaa3643.

Adoptive cellular therapy: a race to the finish line.

Author information

1
Center for Cellular Immunotherapies and the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA. cjune@exchange.upenn.edu sriddell@fredhutch.org t.schumacher@nki.nl.
2
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA. cjune@exchange.upenn.edu sriddell@fredhutch.org t.schumacher@nki.nl.
3
Division of Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands. cjune@exchange.upenn.edu sriddell@fredhutch.org t.schumacher@nki.nl.

Abstract

Adoptive T cell transfer for cancer, chronic infection, and autoimmunity is an emerging field that shows promise in recent trials. Using the principles of synthetic biology, advances in cell culture and genetic engineering have made it possible to generate human T cells that display desired specificities and enhanced functionalities compared with the natural immune system. The prospects for widespread availability of engineered T cells have changed dramatically, given the recent entry of the pharmaceutical industry to this arena. Here, we discuss some of the challenges--such as regulatory, cost, and manufacturing--and opportunities, including personalized gene-modified T cells, that face the field of adoptive cellular therapy.

PMID:
25810311
DOI:
10.1126/scitranslmed.aaa3643
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center